Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | August 25, 2026 | August 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 25, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,596 |
Ending reported balance
After 2026-08-25 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-25 · Exercise / conversion · Acquired 21,132 · Balance 52,728 Row 2 · 2026-08-25 · Exercise / conversion · Acquired 12,429 · Balance 65,157 Row 3 · 2026-08-25 · Sale · Disposed 33,561 · Balance 31,596 F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $194.12 · Expires 2033-05-26 | Direct | 7,044 |
Reported balance
After 2026-08-25 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-25 · Exercise / conversion · Disposed 21,132 · Balance 7,044 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $208.44 · Expires 2034-05-31 | Direct | 12,429 |
Reported balance
After 2026-08-25 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-25 · Exercise / conversion · Disposed 12,429 · Balance 12,429 |
| Common StockSEC Table I · non-derivative | Indirect2024 GRAT | 5,423 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,423 |
| Common StockSEC Table I · non-derivative | Indirect2025 GRAT | 10,780 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 10,780 |
| Common StockSEC Table I · non-derivative | Indirect2026 GRAT | 20,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 20,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 155,611 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 155,611 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust Held By Spouse | 10,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 10,000 |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 25, 2026 Filed Aug 27, 2026 20:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 12,429 | $0.00 Strike: $208.44 | $0.00 |
DisclosureSEC source: 0001100682-26-000140 · form4.xml · derivative · entry 10 FOSTER JAMES C · CIK 0001141722 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,429 Underlying: Common Stock · 12,429 shares Expires 2034-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 20:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 21,132 | $0.00 Strike: $194.12 | $0.00 |
DisclosureSEC source: 0001100682-26-000140 · form4.xml · derivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,044 Underlying: Common Stock · 21,132 shares Expires 2033-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 20:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 33,561 | $300.00 | $10,068,300.00 |
DisclosureSEC source: 0001100682-26-000140 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,596 F1 · shares: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 20:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 12,429 | $208.44 | $2,590,700.76 |
DisclosureSEC source: 0001100682-26-000140 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 20:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 21,132 | $194.12 | $4,102,143.84 |
DisclosureSEC source: 0001100682-26-000140 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 20:35 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 28,733 | $0.00 Strike: $179.66 | $0.00 |
DisclosureSEC source: 0001100682-26-000126 · form4.xml · derivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,733 shares Expires 2030-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 20:35 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 28,733 | $275.00 | $7,901,575.00 |
DisclosureSEC source: 0001100682-26-000126 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,596 F1 · shares: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 20:35 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 28,733 | $179.66 | $5,162,170.78 |
DisclosureSEC source: 0001100682-26-000126 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:59 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 75,000 | $225.00 | $16,875,000.00 |
DisclosureSEC source: 0001100682-26-000111 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,596 F1 · shares: This sale occurred pursuant to a Rule 10b5-1 Trading Plan that was adopted by the reporting person on March 6, 2026. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:25 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001100682-26-000109 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Held By Spouse Disclosed balance after: 10,000 F3 · shares: Reflects the exempt transfer pursuant to Rule 16a-13 of 10,000 shares held by the reporting person's spouse to a revocable trust controlled by the reporting person's spouse. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:25 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001100682-26-000109 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held By Spouse Disclosed balance after: 0 F3 · shares: Reflects the exempt transfer pursuant to Rule 16a-13 of 10,000 shares held by the reporting person's spouse to a revocable trust controlled by the reporting person's spouse. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:25 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001100682-26-000109 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · 2026 GRAT Disclosed balance after: 20,000 F2 · shares: Reflects the exempt transfer pursuant to Rule 16a-13 of 20,000 shares held by the reporting person to a revocable trust controlled by the reporting person. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:25 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001100682-26-000109 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,596 F2 · shares: Reflects the exempt transfer pursuant to Rule 16a-13 of 20,000 shares held by the reporting person to a revocable trust controlled by the reporting person. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:25 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 153,361 | $0.00 | $0.00 |
DisclosureSEC source: 0001100682-26-000109 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 155,611 F1 · shares: Reflects the exempt transfer pursuant to Rule 16a-13 of 153,361 shares held by the reporting person to a revocable trust controlled by the reporting person. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:25 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 153,361 | $0.00 | $0.00 |
DisclosureSEC source: 0001100682-26-000109 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,596 F1 · shares: Reflects the exempt transfer pursuant to Rule 16a-13 of 153,361 shares held by the reporting person to a revocable trust controlled by the reporting person. Read SEC document |
| May 30, 2026 Filed Jun 2, 2026 20:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 1,596 | $180.71 | $288,413.16 |
DisclosureSEC source: 0001100682-26-000091 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,957 Read SEC document |
| May 08, 2026 Filed May 11, 2026 20:25 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 422 | $177.62 | $74,955.64 |
DisclosureSEC source: 0001100682-26-000044 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,553 F2 · shares: The grant was made in lieu of director service fees for the term commencing May 5, 2026. The restricted stock units vest upon the earlier of 5/8/2027, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 08, 2026 Filed May 11, 2026 20:25 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 1,438 | $177.62 | $255,417.56 |
DisclosureSEC source: 0001100682-26-000044 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,131 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 16,796 | $178.61 | $2,999,933.56 |
DisclosureSEC source: 0001100682-26-000026 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,693 F1 · shares: 100% of the unvested restricted stock units vest on March 2, 2028. F2 · balance_after: Reflects the exempt transfer pursuant to Rule 16a-13 of 9,220 shares from the 2025 GRAT account to direct holdings. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 21:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 14,664 | $211.68 | $3,104,075.52 |
DisclosureSEC source: 0001100682-26-000012 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,677 Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 21:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 39,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001100682-26-000012 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,341 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 26, 2023. F2 · balance_after: Reflects the exempt transfer pursuant to Rule 16a-13 of (i) 14,577 shares from the 2024 GRAT account to direct holdings; and (ii) 4,048 shares from the 2022 GRAT account to direct holdings. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 17,253 | $135.63 | $2,340,024.39 |
DisclosureSEC source: 0001127602-25-016539 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,685 F1 · shares: Unvested restricted stock units vest annually on: May 30, 2026; May 30, 2027; May 30, 2028; May 30, 2029. F2 · balance_after: Reflects the exempt transfer pursuant to Rule 16a-13 of 9,793 shares from the reporting person's indirect holdings to the reporting person's direct holdings. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | PurchaseCommon Stock | 6,075 | $165.01 | $1,002,435.75 |
DisclosureSEC source: 0001127602-25-006253 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,639 Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 22:03 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 6,827 | $165.57 | $1,130,346.39 |
DisclosureSEC source: 0001127602-25-002790 · form4.xml · nonDerivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,564 Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 22:03 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 19,608 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-002790 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,391 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 27, 2022. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-027034 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,783 Read SEC document |
| August 12, 2024 Filed Aug 13, 2024 20:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-022073 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,751 Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:04 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 25,000 | $250.00 | $6,250,000.00 |
DisclosureSEC source: 0001127602-24-021581 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,251 F1 · date: This sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on February 26, 2024. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 24,858 | $208.44 Strike: $208.44 | $5,181,401.52 |
DisclosureSEC source: 0001127602-24-017670 · form4.xml · derivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,858 Underlying: Common Stock · 24,858 shares Expires 2034-05-31 F1 · shares: Stock options vest as follows: 6,214 on May 31, 2025, 6,215 on May 31, 2026, 6,214 on May 31, 2027, and 6,215 on May 31, 2028. Read SEC document |
| May 29, 2024 Filed May 30, 2024 22:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 1,274 | $214.51 | $273,285.74 |
DisclosureSEC source: 0001127602-24-017008 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,044 Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 22:28 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-005822 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,613 Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:03 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 10,757 | $220.28 | $2,369,551.96 |
DisclosureSEC source: 0001127602-24-002769 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,613 Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:03 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 24,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-002769 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,370 Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 21:59 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 17,436 | $0.00 Strike: $144.67 | $0.00 |
DisclosureSEC source: 0001127602-24-002765 · form4.xml · derivative · entry 10 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,436 shares Expires 2024-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: The transaction was executed as a net exercise, in which no shares were purchased or sold in the open market. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 21:59 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 12,710 | $224.56 | $2,854,157.60 |
DisclosureSEC source: 0001127602-24-002765 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,117 Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 21:59 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 17,436 | $144.67 | $2,522,466.12 |
DisclosureSEC source: 0001127602-24-002765 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2024 Filed Mar 25, 2024 22:58 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 10,540 | $220.28 | $2,321,751.20 |
DisclosureSEC source: 0001127602-24-011128 · form4a.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,318 Read SEC document |
| January 29, 2024 Filed Mar 25, 2024 22:58 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 23,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-011128 · form4a.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,858 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 28, 2021. Read SEC document |
| November 14, 2023 Filed Nov 15, 2023 14:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | PurchaseCommon Stock | 5,620 | $178.05 | $1,000,641.00 |
DisclosureSEC source: 0001127602-23-027415 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,643 F1 · price: This transaction was executed in multiple trades at prices ranging from $177.99 to $178.11. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 20:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-022484 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,023 Read SEC document |
| May 29, 2023 Filed May 31, 2023 17:38 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 1,274 | $194.12 | $247,308.88 |
DisclosureSEC source: 0001127602-23-017137 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,523 Read SEC document |
| May 26, 2023 Filed May 31, 2023 17:38 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 28,176 | $194.12 Strike: $194.12 | $5,469,525.12 |
DisclosureSEC source: 0001127602-23-017137 · form4.xml · derivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,176 Underlying: Common Stock · 28,176 shares Expires 2033-05-26 F1 · shares: Stock Options vest as follows: 7,044 on May 26, 2024, 7,044 on May 26, 2025, 7,044 on May 26, 2026 and 7,044 on May 26, 2027. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 3,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-015972 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · 2020 GRAT Disclosed balance after: 6,017 F1 · shares: The transaction was a gift of shares formerly held in a trust in the reporting person's name. The shares are no longer owned by the reporting person. F2 · balance_after: On 5/15/2023, 6,017 shares were transferred from the 2020 GRAT account to Direct holdings. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 3,811 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-015972 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · 2020 GRAT Disclosed balance after: 9,829 F1 · shares: The transaction was a gift of shares formerly held in a trust in the reporting person's name. The shares are no longer owned by the reporting person. Read SEC document |
| February 22, 2023 Filed Feb 22, 2023 21:49 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 1,814 | $243.60 | $441,890.40 |
DisclosureSEC source: 0001127602-23-006499 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,780 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:02 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 108 | $250.16 | $27,017.28 |
DisclosureSEC source: 0001127602-23-005808 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,594 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F2 · balance_after: On 2/01/2023: 3,672 shares were transferred from the 2021 GRAT account to Direct Holdings. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:02 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 19,892 | $250.00 | $4,973,000.00 |
DisclosureSEC source: 0001127602-23-005808 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,702 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F2 · balance_after: On 2/01/2023: 3,672 shares were transferred from the 2021 GRAT account to Direct Holdings. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 22:57 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 21,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002783 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,922 F1 · balance_after: On 06/07/2022: 3,939 shares were transferred from the 2020 GRAT account to Direct Holdings. F2 · balance_after: On 10/11/2022, the reporting person contributed 11,000 shares of CRL Common Stock to a grantor retained annuity trust for the benefit of himself and his adult children. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 22:57 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 49,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002783 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,375 F3 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 29, 2020. F1 · balance_after: On 06/07/2022: 3,939 shares were transferred from the 2020 GRAT account to Direct Holdings. F2 · balance_after: On 10/11/2022, the reporting person contributed 11,000 shares of CRL Common Stock to a grantor retained annuity trust for the benefit of himself and his adult children. Read SEC document |
| June 06, 2022 Filed Jan 31, 2023 22:57 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002783 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,711 F1 · balance_after: On 06/07/2022: 3,939 shares were transferred from the 2020 GRAT account to Direct Holdings. F2 · balance_after: On 10/11/2022, the reporting person contributed 11,000 shares of CRL Common Stock to a grantor retained annuity trust for the benefit of himself and his adult children. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.